Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Please note that the Harvard Catalyst apps that use eCommons authentication are unaffected by the recent login changes made by Harvard University.
Keywords
Last Name
Institution

profileDora Dias-Santagata, Ph.D.

TitleAssistant Professor of Pathology
InstitutionMassachusetts General Hospital
DepartmentPathology
AddressMassachusetts General Hospital
GRJ-1028, Translational Research Lab
55 Fruit St
Boston MA 02114
Phone617/724-1261
Fax617/726-6974
vCardDownload vCard (login for email)

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Cipriani NA, Agarwal S, Dias-Santagata D, Faquin WC, Sadow PM. Clear Cell Change in Thyroid Carcinoma: A Clinicopathologic and Molecular Study with Identification of Variable Genetic Anomalies. Thyroid. 2017 Apr 12. PMID: 28293986.
    View in: PubMed
  2. Zhao L, Dias-Santagata D, Sadow PM, Faquin WC. Cytological, molecular, and clinical features of noninvasive follicular thyroid neoplasm with papillary-like nuclear features versus invasive forms of follicular variant of papillary thyroid carcinoma. Cancer. 2017 Feb 13. PMID: 28192645.
    View in: PubMed
  3. Su Y, Goncalves T, Dias-Santagata D, Hoang MP. Immunohistochemical Detection of ROS1 Fusion. Am J Clin Pathol. 2017 Jan 01; 147(1):77-82. PMID: 28007702.
    View in: PubMed
  4. Lawrence NF, Hammond MR, Frederick DT, Su Y, Dias-Santagata D, Deng A, Selim MA, Mahalingam M, Flaherty KT, Hoang MP. Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome. J Am Acad Dermatol. 2016 Sep; 75(3):595-602. PMID: 27543214.
    View in: PubMed
  5. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, Chin E, Parks M, Lee D, DiCecca RH, Lockerman E, Huynh T, Logan J, Ritterhouse LL, Le LP, Muniappan A, Digumarthy S, Channick C, Keyes C, Getz G, Dias-Santagata D, Heist RS, Lennerz J, Sequist LV, Benes CH, Iafrate AJ, Mino-Kenudson M, Engelman JA, Shaw AT. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016 Oct; 6(10):1118-1133. PMID: 27432227.
    View in: PubMed
  6. Heist RS, Sequist LV, Borger D, Gainor JF, Arellano RS, Le LP, Dias-Santagata D, Clark JW, Engelman JA, Shaw AT, Iafrate AJ. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. J Thorac Oncol. 2016 Aug; 11(8):1242-5. PMID: 27343442.
    View in: PubMed
  7. Lucena-Araujo AR, Moran JP, VanderLaan PA, Dias-Santagata D, Folch E, Majid A, Kent MS, Gangadharan SP, Rangachari D, Huberman MS, Kobayashi SS, Costa DB. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. Lung Cancer. 2016 Sep; 99:17-22. PMID: 27565908; PMCID: PMC5002311 [Available on 09/01/17].
  8. Lennerz JK, van der Sloot KW, Le LP, Batten JM, Han JY, Fan KC, Siegel CA, Srivastava A, Park do Y, Chen JH, Sands BE, Korzenik JR, Odze RD, Dias-Santagata D, Borger DR, Khalili H, Iafrate AJ, Lauwers GY. Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer. Int J Colorectal Dis. 2016 May; 31(5):973-82. PMID: 27026089.
    View in: PubMed
  9. Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK, Listewnik ML, Dias-Santagata D, Thorner AR, Van Hummelen P, Brastianos PK, Reardon DA, Wen PY, Al-Mefty O, Ramkissoon SH, Folkerth RD, Ligon KL, Ligon AH, Alexander BM, Dunn IF, Beroukhim R, Santagata S. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 May; 18(5):649-55. PMID: 26826201; PMCID: PMC4827048 [Available on 05/01/17].
  10. Dias-Santagata D, Su Y, Hoang MP. Immunohistochemical Detection of NRASQ61R Mutation in Diverse Tumor Types. Am J Clin Pathol. 2016 Jan; 145(1):29-34. PMID: 26712868.
    View in: PubMed
  11. Duquette M, Sadow PM, Husain A, Sims JN, Antonello ZA, Fischer AH, Song C, Castellanos-Rizaldos E, Makrigiorgos GM, Kurebayashi J, Nose V, Van Hummelen P, Bronson RT, Vinco M, Giordano TJ, Dias-Santagata D, Pandolfi PP, Nucera C. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Oncotarget. 2015 Dec 15; 6(40):42445-67. PMID: 26636651; PMCID: PMC4767444.
  12. Sadow PM, Dias-Santagata D, Zheng Z, Lin DT, Le LP, Nucera C. Identification of insertions in PTEN and TP53 in anaplastic thyroid carcinoma with angiogenic brain metastasis. Endocr Relat Cancer. 2015 Dec; 22(6):L23-8. PMID: 26472209; PMCID: PMC4609031 [Available on 12/01/16].
  13. Dudley JC, Zheng Z, McDonald T, Le LP, Dias-Santagata D, Borger D, Batten J, Vernovsky K, Sweeney B, Arpin RN, Brugge WR, Forcione DG, Pitman MB, Iafrate AJ. Next-Generation Sequencing and Fluorescence in Situ Hybridization Have Comparable Performance Characteristics in the Analysis of Pancreaticobiliary Brushings for Malignancy. J Mol Diagn. 2016 Jan; 18(1):124-30. PMID: 26596524.
    View in: PubMed
  14. Platt MY, Fathi AT, Borger DR, Brunner AM, Hasserjian RP, Balaj L, Lum A, Yip S, Dias-Santagata D, Zheng Z, Le LP, Graubert TA, Iafrate AJ, Nardi V. Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Mol Diagn. 2015 Nov; 17(6):661-8. PMID: 26331834; PMCID: PMC4630164 [Available on 11/01/16].
  15. Jones M, Zheng Z, Wang J, Dudley J, Albanese E, Kadayifci A, Dias-Santagata D, Le L, Brugge WR, Fernandez-del Castillo C, Mino-Kenudson M, Iafrate AJ, Pitman MB. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts. Gastrointest Endosc. 2016 Jan; 83(1):140-8. PMID: 26253016.
    View in: PubMed
  16. Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, Fulton L, Hata AN, Lockerman EL, Kalsy A, Digumarthy S, Muzikansky A, Raponi M, Garcia AR, Mulvey HE, Parks MK, DiCecca RH, Dias-Santagata D, Iafrate AJ, Shaw AT, Allen AR, Engelman JA, Sequist LV. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discov. 2015 Jul; 5(7):713-22. PMID: 25934077; PMCID: PMC4497836 [Available on 01/01/16].
  17. Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May; 10(5):768-77. PMID: 25738220; PMCID: PMC4410843.
  18. Kovach AE, Nucera C, Lam QT, Nguyen A, Dias-Santagata D, Sadow PM. Genomic and immunohistochemical analysis in human adrenal cortical neoplasia reveal beta-catenin mutations as potential prognostic biomarker. Discoveries (Craiova). 2015 Apr-Jun; 3(2). PMID: 26317117.
    View in: PubMed
  19. Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM, Bahl S, Anderka K, Green LM, Lennon NJ, Huynh TG, Mino-Kenudson M, Getz G, Dias-Santagata D, Iafrate AJ, Engelman JA, Garraway LA, Corcoran RB. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discov. 2015 Apr; 5(4):358-67. PMID: 25673644; PMCID: PMC4390490.
  20. Izar B, Zhou H, Heist RS, Azzoli CG, Muzikansky A, Scribner EE, Bernardo LA, Dias-Santagata D, Iafrate AJ, Lanuti M. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. J Thorac Oncol. 2014 Sep; 9(9):1363-9. PMID: 25122432.
    View in: PubMed
  21. McFadden DG, Dias-Santagata D, Sadow PM, Lynch KD, Lubitz C, Donovan SE, Zheng Z, Le L, Iafrate AJ, Daniels GH. Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2014 Nov; 99(11):E2457-62. PMID: 25148236; PMCID: PMC4223441.
  22. Scherz-Shouval R, Santagata S, Mendillo ML, Sholl LM, Ben-Aharon I, Beck AH, Dias-Santagata D, Koeva M, Stemmer SM, Whitesell L, Lindquist S. The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy. Cell. 2014 Jul 31; 158(3):564-78. PMID: 25083868; PMCID: PMC4249939.
  23. Santagata S, Eberlin LS, Norton I, Calligaris D, Feldman DR, Ide JL, Liu X, Wiley JS, Vestal ML, Ramkissoon SH, Orringer DA, Gill KK, Dunn IF, Dias-Santagata D, Ligon KL, Jolesz FA, Golby AJ, Cooks RG, Agar NY. Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Proc Natl Acad Sci U S A. 2014 Jul 29; 111(30):11121-6. PMID: 24982150; PMCID: PMC4121790.
  24. Mordes DA, Lynch K, Campbell S, Dias-Santagata D, Nose V, Louis DN, Hoang MP. VE1 antibody immunoreactivity in normal anterior pituitary and adrenal cortex without detectable BRAF V600E mutations. Am J Clin Pathol. 2014 Jun; 141(6):811-5. PMID: 24838325.
    View in: PubMed
  25. Primiani A, Dias-Santagata D, Iafrate AJ, Kradin RL. Pulmonary adenocarcinoma mutation profile in smokers with smoking-related interstitial fibrosis. Int J Chron Obstruct Pulmon Dis. 2014; 9:525-31. PMID: 24920890; PMCID: PMC4043428.
  26. Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, Dias-Santagata D, Ellisen LW, Borger DR, Fendt SM, Vander Heiden MG, Batchelor TT, Iafrate AJ, Cahill DP, Chi AS. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res. 2014 Jun 01; 20(11):2898-909. PMID: 24714777; PMCID: PMC4070445.
  27. Dienstmann R, Dong F, Borger D, Dias-Santagata D, Ellisen LW, Le LP, Iafrate AJ. Standardized decision support in next generation sequencing reports of somatic cancer variants. Mol Oncol. 2014 Jul; 8(5):859-73. PMID: 24768039.
    View in: PubMed
  28. Lubitz CC, Economopoulos KP, Pawlak AC, Lynch K, Dias-Santagata D, Faquin WC, Sadow PM. Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile. Thyroid. 2014 Jun; 24(6):958-65. PMID: 24417340; PMCID: PMC4046200.
  29. Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, Murphy JE, Faris JE, Dias-Santagata D, Haigis KM, Ellisen LW, Iafrate AJ, Hong TS. Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer. 2014 May 15; 120(10):1482-90. PMID: 24500602; PMCID: PMC4327902.
  30. Brastianos PK, Taylor-Weiner A, Manley PE, Jones RT, Dias-Santagata D, Thorner AR, Lawrence MS, Rodriguez FJ, Bernardo LA, Schubert L, Sunkavalli A, Shillingford N, Calicchio ML, Lidov HG, Taha H, Martinez-Lage M, Santi M, Storm PB, Lee JY, Palmer JN, Adappa ND, Scott RM, Dunn IF, Laws ER, Stewart C, Ligon KL, Hoang MP, Van Hummelen P, Hahn WC, Louis DN, Resnick AC, Kieran MW, Getz G, Santagata S. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014 Feb; 46(2):161-5. PMID: 24413733; PMCID: PMC3982316.
  31. Akhavanfard S, Vargas SO, Han M, Nitta M, Chang CB, Le LP, Fazlollahi L, Nguyen Q, Ma Y, Cosper A, Dias-Santagata D, Han JY, Bergethon K, Borger DR, Ellisen LW, Pomeroy SL, Haber DA, Iafrate AJ, Rivera MN. Inactivation of the tumor suppressor WTX in a subset of pediatric tumors. Genes Chromosomes Cancer. 2014 Jan; 53(1):67-77. PMID: 24249259.
    View in: PubMed
  32. Routhier CA, Mochel MC, Lynch K, Dias-Santagata D, Louis DN, Hoang MP. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum Pathol. 2013 Nov; 44(11):2563-70. PMID: 24071017.
    View in: PubMed
  33. Juric D, Isakoff SJ, Borger DR, Dias-Santagata D, Higgins MJ, Iafrate AJ, Flaherty K, Moy B, Ellisen LW. Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review. J Clin Oncol. 2013 Sep 10; 31(26_suppl):145. PMID: 28136532.
    View in: PubMed
  34. Izar B, Sequist L, Lee M, Muzikansky A, Heist R, Iafrate J, Dias-Santagata D, Mathisen D, Lanuti M. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers. Ann Thorac Surg. 2013 Sep; 96(3):962-8. PMID: 23932319.
    View in: PubMed
  35. Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, Shaw AT. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013 Aug 01; 19(15):4273-81. PMID: 23729361; PMCID: PMC3874127.
  36. Chi AS, Batchelor TT, Yang D, Dias-Santagata D, Borger DR, Ellisen LW, Iafrate AJ, Louis DN. BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol. 2013 May 10; 31(14):e233-6. PMID: 23547069.
    View in: PubMed
  37. Tse JY, Pawlak AC, Boussahmain C, Routhier CA, Dias-Santagata D, Kalomiris D, Hoang MP. Basal cell carcinoma with osteosarcomatous component. Am J Dermatopathol. 2013 Apr; 35(2):261-5. PMID: 23221485.
    View in: PubMed
  38. Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA, Pao W. Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res. 2013 May 01; 19(9):2584-91. PMID: 23515407; PMCID: PMC3643999.
  39. Onozato ML, Kovach AE, Yeap BY, Morales-Oyarvide V, Klepeis VE, Tammireddy S, Heist RS, Mark EJ, Dias-Santagata D, Iafrate AJ, Yagi Y, Mino-Kenudson M. Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis. Am J Surg Pathol. 2013 Feb; 37(2):287-94. PMID: 23095504; PMCID: PMC3545070.
  40. Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, Song Y, Lifshits E, Hung KE, Shioda T, Dias-Santagata D, Singh A, Settleman J, Benes CH, Mino-Kenudson M, Wong KK, Engelman JA. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell. 2013 Jan 14; 23(1):121-8. PMID: 23245996; PMCID: PMC3667614.
  41. Santamaria-Barria JA, Boland GM, Yeap BY, Nardi V, Dias-Santagata D, Cusack JC. Merkel cell carcinoma: 30-year experience from a single institution. Ann Surg Oncol. 2013 Apr; 20(4):1365-73. PMID: 23208132.
    View in: PubMed
  42. Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res. 2013 Jan 15; 19(2):480-90. PMID: 23186780.
    View in: PubMed
  43. Le LP, Dias-Santagata D, Pawlak AC, Cosper AK, Nguyen AT, Selim MA, Deng A, Horick NK, Iafrate AJ, Mihm MC, Hoang MP. Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses. PLoS One. 2012; 7(10):e47290. PMID: 23056620; PMCID: PMC3467209.
  44. Louissaint A, Ackerman AM, Dias-Santagata D, Ferry JA, Hochberg EP, Huang MS, Iafrate AJ, Lara DO, Pinkus GS, Salaverria I, Siddiquee Z, Siebert R, Weinstein HJ, Zukerberg LR, Harris NL, Hasserjian RP. Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. Blood. 2012 Sep 20; 120(12):2395-404. PMID: 22855608.
    View in: PubMed
  45. Chi AS, Batchelor TT, Dias-Santagata D, Borger D, Stiles CD, Wang DL, Curry WT, Wen PY, Ligon KL, Ellisen L, Louis DN, Iafrate AJ. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012 Oct; 110(1):89-98. PMID: 22821383; PMCID: PMC3583376.
  46. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012 Jul 31; 109(31):E2127-33. PMID: 22773810; PMCID: PMC3411967.
  47. Nishino M, Klepeis VE, Yeap BY, Bergethon K, Morales-Oyarvide V, Dias-Santagata D, Yagi Y, Mark EJ, Iafrate AJ, Mino-Kenudson M. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol. 2012 Nov; 25(11):1462-72. PMID: 22743652.
    View in: PubMed
  48. Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One. 2012; 7(4):e35309. PMID: 22536370; PMCID: PMC3335021.
  49. Nardi V, Song Y, Santamaria-Barria JA, Cosper AK, Lam Q, Faber AC, Boland GM, Yeap BY, Bergethon K, Scialabba VL, Tsao H, Settleman J, Ryan DP, Borger DR, Bhan AK, Hoang MP, Iafrate AJ, Cusack JC, Engelman JA, Dias-Santagata D. Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res. 2012 Mar 01; 18(5):1227-36. PMID: 22261808; PMCID: PMC3912509.
  50. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012 Mar; 2(3):227-35. PMID: 22448344; PMCID: PMC3308191.
  51. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012; 17(1):72-9. PMID: 22180306; PMCID: PMC3267826.
  52. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, Wain JC, Gaissert H, Donahue DM, Muniappan A, Wright C, Willers H, Mathisen DJ, Choi NC, Baselga J, Lynch TJ, Ellisen LW, Mino-Kenudson M, Lanuti M, Borger DR, Iafrate AJ, Engelman JA, Dias-Santagata D. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011 Dec; 22(12):2616-24. PMID: 22071650; PMCID: PMC3493130.
  53. Linskey KR, Dias-Santagata D, Nazarian RM, Le LP, Lam Q, Bellucci KS, Robinson-Bostom L, Mihm MC, Hoang MP. Malignant neurocristic hamartoma: a tumor distinct from conventional melanoma and malignant blue nevus. Am J Surg Pathol. 2011 Oct; 35(10):1570-7. PMID: 21934481.
    View in: PubMed
  54. Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, Muzikansky A, Lifshits E, Roberge S, Coffman EJ, Benes CH, Gómez HL, Baselga J, Arteaga CL, Rivera MN, Dias-Santagata D, Jain RK, Engelman JA. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov. 2011 Sep; 1(4):352-65. PMID: 22145099; PMCID: PMC3229203.
  55. Russo AL, Borger DR, Ryan DP, Fan KC, Lopez H, Scialabba V, Blaszkowsky LS, Kwak EL, Clark JW, Allen JN, Wadlow RC, Zhu AX, Wang R, Dias-Santagata D, Hong TS, Iafrate AJ. Mutational analysis and clinical correlation of 185 consecutive metastatic colorectal patients: Similarities and differences between colon and rectal patients. J Clin Oncol. 2011 May 20; 29(15_suppl):3536. PMID: 28020316.
    View in: PubMed
  56. Sequist LV, Heist RS, Shaw AT, Fidias P, Temel JS, Lennes IT, Bast E, Waltman BA, Lanuti M, Muzikansky A, Mino-Kenudson M, Iafrate AJ, Borger DR, Dias-Santagata D, Engelman JA. SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice. J Clin Oncol. 2011 May 20; 29(15_suppl):7518. PMID: 28023280.
    View in: PubMed
  57. Wirth LJ, Nardi V, Juric D, Cosper AK, Bergethon K, Scialabba V, Borger DR, Iafrate AJ, Ellisen LW, Deschler D, Zhao D, Sadow PM, Dias-Santagata D. Detection of novel genetic aberrations in salivary duct carcinoma (SDC) by SNaPshot analysis. J Clin Oncol. 2011 May 20; 29(15_suppl):5579. PMID: 28022120.
    View in: PubMed
  58. Demicco EG, Farris AB, Baba Y, Agbor-Etang B, Bergethon K, Mandal R, Daives D, Fukuoka J, Shimizu M, Dias-Santagata D, Ogino S, Iafrate AJ, Gaissert HA, Mino-Kenudson M. The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma. Mod Pathol. 2011 Sep; 24(9):1177-90. PMID: 21572404.
    View in: PubMed
  59. Xiao HD, Yamaguchi H, Dias-Santagata D, Kuboki Y, Akhavanfard S, Hatori T, Yamamoto M, Shiratori K, Kobayashi M, Shimizu M, Fernandez-Del Castillo C, Mino-Kenudson M, Furukawa T. Molecular characteristics and biological behaviours of the oncocytic and pancreatobiliary subtypes of intraductal papillary mucinous neoplasms. J Pathol. 2011 Aug; 224(4):508-16. PMID: 21547907.
    View in: PubMed
  60. Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, Batchelor TT, Ligon KL, Iafrate AJ, Ligon AH, Louis DN, Santagata S. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011 Mar 29; 6(3):e17948. PMID: 21479234; PMCID: PMC3066220.
  61. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011 Mar 23; 3(75):75ra26. PMID: 21430269; PMCID: PMC3132801.
  62. Dias-Santagata D, Lam Q, Bergethon K, Baker GM, Iafrate AJ, Rakheja D, Hoang MP. A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas. Mod Pathol. 2011 Jul; 24(7):974-82. PMID: 21423156.
    View in: PubMed
  63. Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Cosper AK, Dias-Santagata D, Nutt CL, Iafrate AJ, Louis DN. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neuropathol Exp Neurol. 2011 Feb; 70(2):110-5. PMID: 21343879; PMCID: PMC3061457.
  64. Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, Chung CH, Massion PP, Vnencak-Jones CL, Iafrate AJ, Pao W. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn. 2011 Jan; 13(1):74-84. PMID: 21227397; PMCID: PMC3070558.
  65. Growdon WB, Roussel BN, Scialabba VL, Foster R, Dias-Santagata D, Iafrate AJ, Ellisen LW, Tambouret RH, Rueda BR, Borger DR. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecol Oncol. 2011 Apr; 121(1):212-7. PMID: 21168197.
    View in: PubMed
  66. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal. 2010 Nov 23; 3(149):ra84. PMID: 21098728; PMCID: PMC3372405.
  67. Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM, Ogino S. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol. 2010 Sep; 19(3):157-63. PMID: 20736745; PMCID: PMC2929976.
  68. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010 May; 2(5):146-58. PMID: 20432502; PMCID: PMC3377316.
  69. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010 Jan 19; 17(1):77-88. PMID: 20129249; PMCID: PMC2980857.
  70. Staats PN, Garcia JJ, Dias-Santagata DC, Kuhlmann G, Stubbs H, McCluggage WG, De Nictolis M, Kommoss F, Soslow RA, Iafrate AJ, Oliva E. Uterine tumors resembling ovarian sex cord tumors (UTROSCT) lack the JAZF1-JJAZ1 translocation frequently seen in endometrial stromal tumors. Am J Surg Pathol. 2009 Aug; 33(8):1206-12. PMID: 19542872.
    View in: PubMed
  71. Growdon WB, Boisvert SL, Akhavanfard S, Oliva E, Dias-Santagata DC, Kojiro S, Horowitz NS, Iafrate AJ, Borger DR, Rueda BR. Decreased survival in EGFR gene amplified vulvar carcinoma. Gynecol Oncol. 2008 Nov; 111(2):289-97. PMID: 18768215.
    View in: PubMed
  72. Nanda A, Dias-Santagata DC, Stubbs H, O'Hara CJ, Zaner KS, Lynch TJ, Willers H. Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer. Clin Lung Cancer. 2008 Sep; 9(5):285-7. PMID: 18824451.
    View in: PubMed
  73. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008 Jun 15; 68(12):4853-61. PMID: 18559533; PMCID: PMC2692356.
  74. Xu X, Sarikas A, Dias-Santagata DC, Dolios G, Lafontant PJ, Tsai SC, Zhu W, Nakajima H, Nakajima HO, Field LJ, Wang R, Pan ZQ. The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation. Mol Cell. 2008 May 23; 30(4):403-14. PMID: 18498745; PMCID: PMC2633441.
  75. Steinhilb ML, Dias-Santagata D, Fulga TA, Felch DL, Feany MB. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell. 2007 Dec; 18(12):5060-8. PMID: 17928404; PMCID: PMC2096612.
  76. Steinhilb ML, Dias-Santagata D, Mulkearns EE, Shulman JM, Biernat J, Mandelkow EM, Feany MB. S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila. J Neurosci Res. 2007 May 01; 85(6):1271-8. PMID: 17335084.
    View in: PubMed
  77. Dowell JD, Tsai SC, Dias-Santagata DC, Nakajima H, Wang Z, Zhu W, Field LJ. Expression of a mutant p193/CUL7 molecule confers resistance to MG132- and etoposide-induced apoptosis independent of p53 or Parc binding. Biochim Biophys Acta. 2007 Mar; 1773(3):358-66. PMID: 17229476; PMCID: PMC1876763.
  78. Dias-Santagata D, Fulga TA, Duttaroy A, Feany MB. Oxidative stress mediates tau-induced neurodegeneration in Drosophila. J Clin Invest. 2007 Jan; 117(1):236-45. PMID: 17173140; PMCID: PMC1697799.
  79. Huber C, Dias-Santagata D, Glaser A, O'Sullivan J, Brauner R, Wu K, Xu X, Pearce K, Wang R, Uzielli ML, Dagoneau N, Chemaitilly W, Superti-Furga A, Dos Santos H, Mégarbané A, Morin G, Gillessen-Kaesbach G, Hennekam R, Van der Burgt I, Black GC, Clayton PE, Read A, Le Merrer M, Scambler PJ, Munnich A, Pan ZQ, Winter R, Cormier-Daire V. Identification of mutations in CUL7 in 3-M syndrome. Nat Genet. 2005 Oct; 37(10):1119-24. PMID: 16142236.
    View in: PubMed
  80. Mohn D, Chen SW, Dias DC, Weinstein DC, Dyer MA, Sahr K, Ducker CE, Zahradka E, Keller G, Zaret KS, Gudas LJ, Baron MH. Mouse Mix gene is activated early during differentiation of ES and F9 stem cells and induces endoderm in frog embryos. Dev Dyn. 2003 Mar; 226(3):446-59. PMID: 12619131.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Dias-Santagata's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_